OptiRTP Presents U.S. Expansion Strategy to 40+ Investors at Auckland Briefing
Heath Mills, Chief Executive of the New Zealand Cricket Players’ Association, addresses investors at Buddle Findlay, Auckland
OptiRTP presented its U.S. market entry strategy and clinical validation roadmap to more than 40 current and prospective investors at a private briefing held at Buddle Findlay’s Auckland office on 6 November 2025.
The briefing outlined OptiRTP’s planned U.S. operational headquarters, a clinical validation program with a VA-affiliated university hospital, and the pathway toward FDA Class II registration for its Optimum Bio Sound Therapy (OBST) neuromodulation platform.
Attendees included Sir Graham Henry, Lady Raewyn Henry, Mark Richardson, and Monalisa Codling. Former Paralympian and Wheel Blacks Coach Grant Sharman served as MC.
“I still don’t fully understand the science. But what matters is that people I trust have used it and say it works.”
Heath Mills, Chief Executive of the New Zealand Cricket Players’ Association, spoke about his decision to invest. Black Caps bowlers Kyle Jamieson and Henry Shipley are also investors.
Video testimonials were presented from Black Ferns captain Sarah Hirini, Wallabies head coach Joe Schmidt, and sports executives Simon Tremain and Matt Blair.
“I think this is the next New Zealand unicorn. I could see huge opportunities.”
Mike Hearn, Executive Director of AmCham NZ, along with the U.S. Commercial Service in New Zealand, connected OptiRTP with senior officials in Utah and a visiting U.S. business delegation to discuss establishment of U.S. operational headquarters.
About OptiRTP
OptiRTP (Return to Play) is a New Zealand-based biotech company. Its core technology, OBST (Optimum Bio Sound Therapy), has 352,000+ documented therapy hours with zero serious adverse events reported. OBST is an FDA-registered Class I medical device, 510(k)-exempt (registration and listing, not FDA clearance or approval), that uses dynamic, patterned acoustic neuromodulation via the auditory pathway, with a proposed mechanism involving modulation of central autonomic regulatory networks associated with sleep, pain, recovery and stress regulation. Drug-free and non-invasive, used passively during sleep or rest through a tablet and earbuds. Users can follow recovery markers on their own wearable.
